Cargando…
Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension
Glaucoma is a collection of diseases characterized by multifactorial progressive changes leading to visual field loss and optic neuropathy most frequently due to elevated intraocular pressure (IOP). The goal of treatment is the lowering of the IOP to prevent additional optic nerve damage. Treatment...
Autores principales: | Bell, Nicholas P, Ramos, José L, Feldman, Robert M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2993108/ https://www.ncbi.nlm.nih.gov/pubmed/21139674 http://dx.doi.org/10.2147/OPTH.S14054 |
Ejemplares similares
-
Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops
por: Inoue, Kenji, et al.
Publicado: (2015) -
The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies
por: Radcliffe, Nathan M
Publicado: (2014) -
Quality of dorzolamide hydrochloride and timolol maleate containing eye drops distributed online
por: Merczel, Sára, et al.
Publicado: (2023) -
Efficacy, safety and tolerability of combination therapy with timolol and dorzolamide in glaucoma and ocular hypertension
por: Ichhpujani, Parul, et al.
Publicado: (2010) -
Intraocular pressure reduction of fixed combination timolol maleate 0.5% and dorzolamide 2% (Cosopt) administered three times a day
por: Shemesh, Gabi, et al.
Publicado: (2012)